Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer



Status:Terminated
Conditions:Lung Cancer, Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/15/2018
Start Date:February 11, 2014
End Date:June 21, 2016

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent

The purpose of this study was to determine if ruxolitinib, in combination with
Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of
nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

The study consisted of an open-label, safety run-in (consisting of 1 to 4 cohorts of 9
participants each), to confirm the safety of ruxolitinib in combination with
pemetrexed/cisplatin in participants with nonsquamous non-small cell lung cancer (NSCLC) that
is Stage IIIB, Stage IV, or recurrent. Participants in the safety run-in received open-label
ruxolitinib and pemetrexed and cisplatin.

In the second part of the study, participants enrolled and randomized and received pemetrexed
and cisplatin (open-label) and either ruxolitinib or placebo in a blinded manner. The dose of
ruxolitinib administered was determined from the data produced in the safety run-in phase.

Treatment consisted of repeating 21-day cycles. Participants received infusions of pemetrexed
and cisplatin on Day 1 of each cycle and ruxolitinib/placebo was self-administered during the
entire cycle. Maintenance therapy with ruxolitinib or placebo in combination with pemetrexed,
based on the original treatment assignment, was allowed for participants eligible for
maintenance therapy.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage
IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery,
or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).

- Radiographically measurable or evaluable disease.

- Life expectancy of at least 12 weeks.

- Tumor without activating driver mutations for which there is available therapy (eg,
tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).

- An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:

- Criteria:

- C-reactive protein >10 mg/L AND albumin ≥35 g/L; Score = 1

- C-reactive protein >10 mg L AND albumin <35 g/L; Score = 2

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

- Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified
laboratory parameters at the screening visit.

Exclusion Criteria:

- Squamous or mixed histology (eg, adenosquamous) NSCLC

- Previous systemic therapy for advanced or metastatic disease.

- Known active central nervous system (CNS) metastases.

- Current or previous other malignancy within 2 years of study entry, except cured basal
or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial
neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy
without sponsor approval.

- Current uncontrolled cardiac disease such as angina or myocardial infarction,
congestive heart failure including New York Heart Association functional
classification of 3, or arrhythmia requiring treatment.

- Uncontrolled concomitant medical conditions, including, but not limited to, renal,
hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral,
or psychiatric diseases.
We found this trial at
30
sites
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Canton, OH
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
?
mi
from
Fresno, CA
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Joliet, IL
Click here to add this to my saved trials
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
?
mi
from
Kennewick, WA
Click here to add this to my saved trials
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
?
mi
from
Leesburg, VA
Click here to add this to my saved trials
?
mi
from
Lone Tree, CO
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Norwich, CT
Click here to add this to my saved trials
?
mi
from
Ogden, UT
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Reno, NV
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Southington, CT
Click here to add this to my saved trials
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials